Raltegravir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
RALTEGRAVIR: Repurposing Assessment Pending — Evidence Pack Incomplete
One-Sentence Summary
RALTEGRAVIR (DrugBank: DB06817) is a known antiretroviral agent; however, the current evidence pack contains no TxGNN-predicted new indications, no mechanism of action data, and no safety records. Without predicted indications or supporting evidence, a full drug repurposing evaluation cannot be completed at this stage. This report documents the data gaps and outlines the remediation steps required before proceeding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current evidence pack |
| Predicted New Indication | None — TxGNN predictions not yet generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assessable |
| Germany Market Status | Not found (0 authorizations in current data) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Three critical data layers are missing — TxGNN repurposing predictions, mechanism of action, and safety profile — making it impossible to evaluate any new therapeutic indication at this time.
To proceed, the following is needed:
- Run TxGNN inference for RALTEGRAVIR (DB06817) to generate candidate predicted indications with confidence scores
- Retrieve MOA from DrugBank via API (DB06817) — currently classified as a data gap of High severity; required for mechanistic plausibility analysis
- Obtain package insert (TFDA or EMA/BfArM source) to extract key warnings, contraindications, and drug–drug interactions — currently classified as a Blocking data gap
- Verify Germany market status via BfArM database — RALTEGRAVIR (brand: Isentress, MSD) holds EMA marketing authorisation; the current zero-result may reflect a query scope issue rather than true non-registration
- Once the above data is collected, re-generate this evidence pack (target version v5+) and re-run the full evaluation pipeline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.